<DOC>
	<DOC>NCT02660840</DOC>
	<brief_summary>To establish bioequivalence between new film-coated tablet formulations of 0.5 mg, 1 mg and 5 mg flupentixol and the marketed coated tablet formulations of 0.5 mg, 1 mg, and 5 mg flupentixol, administered as single doses</brief_summary>
	<brief_title>Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations</brief_title>
	<detailed_description>All subjects will be confined to the clinic from Day -1 (Baseline) until Day 6 (120 hours post-dose) for each dosing period. First and second dosing will be separated by a washout period of at least 21 days</detailed_description>
	<mesh_term>Flupenthixol</mesh_term>
	<mesh_term>Flupenthixol decanoate</mesh_term>
	<criteria>body mass index (BMI) of ≥18.5 and ≤30 kg/m2 The subject is, in the opinion of the investigator, generally healthy based on medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the haematology, clinical chemistry, urinalysis, serology, and other laboratory tests. The subject is pregnant or breastfeeding. The subject has taken any investigational medicinal products 3 months prior to the first dose The subject has tested positive at the Screening Visit or at the Baseline Visit for drugs of abuse (opiates, methadone, cocaine, amphetamines [including ecstasy], barbiturates, benzodiazepines, and cannabinoids). Other protocol defined inclusion and exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>